Recurrent Ovarian Cancer · Secondary Cytoreduction vs Systemic Therapy
Platinum-sensitive + AGO-positive (ECOG 0/no residual/ascites ≤500 ml) + completely resectable → secondary cytoreduction (DESKTOP III); platinum-resistant non-platinum single agent, no surgery.
Platinum-resistant → non-platinum systemic therapy: Platinum-resistant (recurrence <6 months) → non-platinum single-agent chemotherapy ± bevacizumab; generally no secondary cytoreduction (agg…
Step-by-step decision
Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.
🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).
Full pathway
- [Decision] Platinum sensitivity + AGO/resectabilityPlatinum-sensitive (≥6 months after last platinum)? AGO score? Completely resectable? (Positive AGO score = ECOG 0 + no residual after primary surgery + ascites ≤500 ml (predicts complete resection).)
- Platinum-sensitive, AGO-positive, completely resectable → Platinum-sensitive resectable → secondary cytoreduction
- Platinum-sensitive but not completely resectable/AGO-negative → Platinum-sensitive not resectable → platinum-based chemotherapy
- Platinum-resistant (recurrence <6 months) → Platinum-resistant → non-platinum systemic therapy
- [End] Platinum-sensitive resectable → secondary cytoreductionPlatinum-sensitive, AGO-positive, complete resection achievable → secondary cytoreductive surgery (SCS) + platinum-based chemotherapy (DESKTOP III: SCS improves OS, greatest benefit with complete resection) ± bevacizumab/PARP maintenance.
- [End] Platinum-sensitive not resectable → platinum-based chemotherapyPlatinum-sensitive but not completely resectable/AGO-negative → platinum-based combination chemotherapy ± bevacizumab + PARP maintenance (BRCA/HRD); do not force surgery.
- [End] Platinum-resistant → non-platinum systemic therapyPlatinum-resistant (recurrence <6 months) → non-platinum single-agent chemotherapy ± bevacizumab; generally no secondary cytoreduction (aggressive, little benefit); mainly palliative, encourage clinical trials.
Source guidelines & references
- Secondary cytoreduction in recurrent ovarian cancer (AGO DESKTOP III; NCCN; platinum-sensitivity stratification)
This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.